Prevention of spontaneous tumor development in a ret transgenic mouse model by ret peptide vaccination with indoleamine 2,3-dioxygenase inhibitor 1-methyl tryptophan

Cancer Research

Volumn 69, Issue 9, 2009, Pages 3963-3970

  Zeng, Jun ^a,b   Cai, Shaohui ^c   Yi, Yanmei ^a   He, Yuwen ^a   Wang, Zhen ^a   Jiang, Guangmin ^a   Li, Xiaokun ^d   Du, Jun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c JINAN UNIVERSITY   (China)

^d WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL TRYPTOPHAN; CANCER ANTIBODY; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; PEPTIDE VACCINE; PROTEIN RET; RET PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CARCINOMA; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MALE; MOUSE; MT RET 304 B6 MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; SPLEEN; T LYMPHOCYTE ACTIVATION; TH1 CELL; THERAPY EFFECT; TRANSGENIC MOUSE; TREATMENT OUTCOME; TREATMENT RESPONSE; WILD TYPE;

ANIMALS; CANCER VACCINES; CPG ISLANDS; FEMALE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LYMPH NODES; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; PROTO-ONCOGENE PROTEINS C-RET; SPLEEN; T-LYMPHOCYTES; TRYPTOPHAN;

EID: 65949095037     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2476     Document Type: Article

References (41)

1. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985; 42: 581-8.
2. Airaksinen MS, Saarma M. The GDNF family:signalling, biological functions and therapeutic value. Nat Rev 2002; 3: 383-94.
3. Salomon R, Attie T, Amiel J, Pelet A, Niaudet P, Lyonnet S. RET proto-oncogene:role in kidney development and molecular pathology. Adv Nephrol Necker Hospital 1998; 28: 401-17.
4. Kouvaraki MA, Shapiro SE, Perrier ND, et al. RET proto-oncogene:a review and update of genotypephenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 2005; 15: 531-44.
5. Kodama Y, Asai N, Kawai K, et al. The RET protooncogene:a molecular therapeutic target in thyroid cancer. Cancer Sci 2005; 96: 143-8.
6. Jain S, Naughton CK, Yang M, et al. Mice expressing a dominant-negative Ret mutation phenocopy human Hirschsprung disease and delineate a direct role of Ret in spermatogenesis. Development 2004; 131: 5503-13.
7. Plaza-Menacho I, Burzynski GM, de Groot JW, Eggen BJ, Hofstra RM. Current concepts in RET-related genetics, signaling and therapeutics. Trends Genet 2006; 22: 627-36.
8. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363: 458-60.
9. Carlson KM, Dou S, Chi D, et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A 1994; 91: 1579-83.
10. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993; 2: 851-6.
11. Hoff AO, Hoff PM. Medullary thyroid carcinoma. Hematol Oncol Clin North Am 2007; 21: 475-88; viii.
12. Yao JC, Hoff PM. Molecular targeted therapy for neuroendocrine tumors. Hematol Oncol Clin North Am 2007; 21: 575-81; x.
13. Munn DH, Mellor AL. Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007; 117: 1147-54.
14. Lee JR, Dalton RR, Messina JL, et al. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest 2003; 83: 1457-66.
15. Munn DH, Sharma MD, Hou D, et al. Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004; 114: 280-90.
16. Fallarino F, Grohmann U, Hwang KW, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003; 4: 1206-12.
17. Frumento G, Rotondo R, Tonetti M, Ferrara GB. T cell proliferation is blocked by indoleamine 2, 3-dioxygenase. Transplant Proc 2001; 33: 428-30.
18. Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH. Cells expressing indoleamine 2, 3-dioxygenase inhibit T cell responses. J Immunol 2002; 168: 3771-6.
19. Mellor AL, Munn DH. IDO expression by dendritic cells:tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762-74.
20. Baban B, Hansen AM, Chandler PR, et al. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int Immunol 2005; 17: 909-19.
21. + dendritic cells to acquire potent indoleamine 2, 3-dioxygenase-dependent T cell regulatory functions via IFN type 1 signaling. J Immunol 2005; 175: 5601-5.
22. Seo SK, Choi JH, Kim YH, et al. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 2004; 10: 1088-94.
23. Wobser M, Voigt H, Houben R, et al. Dendritic cell based antitumor vaccination:impact of functional indoleamine 2, 3-dioxygenase expression. Cancer Immunol Immunother 2007; 56: 1017-24.
24. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2, 3- dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005; 11: 312-9.
25. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med 2003; 9: 1269-74.
26. Friberg M, Jennings R, Alsarraj M, et al. Indoleamine 2, 3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 2002; 101: 151-5.
27. Hou DY, Muller AJ, Sharma MD, et al. Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007; 67: 792-801.
28. Iwamoto T, Takahashi M, Ito M, et al. Aberrant melanogenesis and melanocytic tumour development in transgenic mice that carry a met allothionein/ret fusion gene. EMBO J 1991; 10: 3167-75.
29. Kato M, Takahashi M, Akhand AA, et al. Transgenic mouse model for skin malignant melanoma. Oncogene 1998; 17: 1885-8.
30. + T cells. Cancer Res 2004; 64: 1496-501.
31. Ito T, Amakawa R, Kaisho T, et al. Interferon-a and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 2002; 195: 1507-12.
32. Krug A, Towarowski A, Britsch S, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001; 31: 3026-37.
33. Choi BK, Asai T, Vinay DS, Kim YH, Kwon BS. 4-1BB- mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2, 3-dioxygenasedependent mechanisms. Cytokine 2006; 34: 233-42.
34. Curti A, Pandolfi S, Valzasina B, et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood 2007; 109: 2871-7.
35. Ou X, Cai S, Liu P, et al. Enhancement of dendritic cell-tumor fusion vaccine potency by indoleaminepyrrole 2, 3-dioxygenase inhibitor, 1-MT. J Cancer Res Clin Oncol 2007; 134: 525-33.
36. Larkin J III, Rankin AL, Picca CC, et al. CD4+CD25+ regulatory T cell repertoire formation shaped by differential presentation of peptides from a self-antigen. J Immunol 2008; 180: 2149-57.
37. + regulatory T cells in murine models of organ-specific autoimmune disease. Cell Immunol 2008; 251: 8-18.
38. Ozaki Y, Edelstein MP, Duch DS. Induction of indoleamine 2, 3-dioxygenase:a mechanism of the antitumor activity of interferon g. Proc Natl Acad Sci U S A 1988; 85: 1242-6.
39. Takikawa O, Kuroiwa T, Yamazaki F, Kido R. Mechanism of interferon-γaction. Characterization of indoleamine 2, 3-dioxygenase in cultured human cells induced by interferon-γand evaluation of the enzymemediated tryptophan degradation in its anticellular activity. J Biol Chem 1988; 263: 2041-8.
40. Yoshida R, Park SW, Yasui H, Takikawa O. Tryptophan degradation in transplanted tumor cells undergoing rejection. J Immunol 1988; 141: 2819-23.
41. Yu WG, Yamamoto N, Takenaka H, et al. Molecular mechanisms underlying IFN-γ-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. Int Immunol 1996; 8: 855-65.